MedTrace Logo

Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

NCT00043316 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2007-11-01

No results posted yet for this study

Summary

The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a week for 12 weeks.

The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is the condition being examined in this study.

Conditions

Interventions

DRUG

interferon gamma-1b

500 or 1000 mcg, inhalation, 3x per week

Sponsors & Collaborators

  • InterMune

    lead INDUSTRY

Principal Investigators

  • Steve Porter, MD · InterMune

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-02-28
Completion
2002-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00043316 on ClinicalTrials.gov